Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine.
Sponsor: GlaxoSmithKline
A PHASE1 clinical study on Plasmodium Falciparum Malaria, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2003. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Jun 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Kenya Medical Research Institute
- The PATH Malaria Vaccine Initiative (MVI)
- U.S. Army Medical Research and Development Command
- United States Agency for International Development (USAID)
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .